南非寻求在当地生产艾滋病毒药物Lenacapavir,以改善撒哈拉以南非洲的药品供应。 South Africa seeks local production of HIV drug lenacapavir to improve access in sub-Saharan Africa.

南非正与UnitedAid和美国药店合作,在当地生产Gilead的长效艾滋病毒药物Lenacapavir, 以便增加整个撒哈拉以南非洲的药品供应, South Africa is pursuing local production of Gilead’s long-acting HIV drug lenacapavir to boost access across sub-Saharan Africa, working with Unitaid and the U.S. Pharmacopoeia to identify a domestic manufacturer. 虽然Gilead向印度、埃及和巴基斯坦的通用制造商颁发了6个2024年许可证,但没有南非公司被包括在内,这促使人们要求获得第7个许可证。 Though Gilead granted six 2024 licenses to generic makers in India, Egypt, and Pakistan, no South African firms were included, prompting calls for a seventh license. Gilead说,在批准任何新的许可证之前,它将对质量建议进行评估。 Gilead says it will assess proposals for quality before approving any new license. 当地生产可以帮助满足日益增长的需求,减少对进口的依赖,扩大巴西等中等收入国家的准入。 Local production could help meet growing demand, reduce reliance on imports, and expand access to middle-income countries like Brazil. 专家们说,广泛使用lenacapavir可以帮助结束艾滋病毒的流行。 Experts say widespread use of lenacapavir could help end the HIV epidemic.